The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2025 | Therapeutic approaches in development for advanced-phase MPNs
In this interview, Olatoyosi Odenike, MD, University of Chicago, Chicago, IL, comments on the promising investigational agents in development for advanced-phase myeloproliferative neoplasms (MPNs), which she defines as patients with accelerated/blast-phase (AP/BP) MPNs and those patients who have not responded to or progressed following JAK inhibitor treatment. This interview took place at the 2nd Annual MPN Workshop of the Carolinas, held in Charlotte, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We are in a wonderful time for advanced phase MPNs, which I define rather broadly to include patients with accelerated and blast phase MPNs, as well as patients with MPNs who may not have responded or have progressed following a JAK inhibitor. And so for those patients, there are a number of exciting new agents under development. These include, for patients who are IDH1- or IDH2-mutated, clinical trials focusing specifically on that subset of patients...
We are in a wonderful time for advanced phase MPNs, which I define rather broadly to include patients with accelerated and blast phase MPNs, as well as patients with MPNs who may not have responded or have progressed following a JAK inhibitor. And so for those patients, there are a number of exciting new agents under development. These include, for patients who are IDH1- or IDH2-mutated, clinical trials focusing specifically on that subset of patients. There are also a number of other investigational agents in development for individuals who may not express IDH1 mutations, for example. Top of that list would be a new investigational category of drugs called LSD1 inhibitors. They are epigenetic modulators. They’re being investigated in various spaces now in the MPNs, including individuals with advanced-phase MPNs. And I’m very excited to see how those trials turn out. And finally, I would be remiss if I didn’t talk about or mention briefly a category of immunotherapeutic agents, which are now finding their way, interestingly, into advanced phase MPNs, specifically for individuals with calreticulin-mutated myeloproliferative neoplasms. There has never been a more exciting time.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
